A Phase 2 study of Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab in Newly Diagnosed Glioblastoma
Recruiting Phase 3 NCT05271240
Study Description
Evaluating the Effectiveness of Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab Combined with Temozolomide and Radiation Therapy in Newly Diagnosed Glioblastoma Patients
Study Details
- Registry ID:
- NCT05271240
- Conditions:
- Glioblastoma, Glioblastoma Multiforme, Glioma, Malignant, GBM, Brain Cancer, Glioblastoma, IDH-wildtype, Glioblastoma Multiforme, Adult
- Phase:
- Phase 3
- Target Enrollment:
- 432 participants
- Start Date:
- Age Range:
- 18–999 years
- Healthy Volunteers:
- No
Study Locations (1 site)
-
Lenox Hill Brain Tumor Center
New York, New York, United States
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.